For years, midbodies were dismissed as mere cellular waste from cell division. But research is shifting this perspective! Recent studies reveal

aMBR, an emerging biotechnology company focused on developing an accessible, non-invasive early-stage multi-cancer screening test using liquid biopsy, has been